email.
Novavax’s COVID-19 vaccine has an overall efficacy of 89.7 percent, with 100 percent efficacy against severe disease, according to final results of its phase 3 trial in the United Kingdom. The results, released Thursday and not yet published in a peer-reviewed journal, showed 96.4 efficacy against the original strain of the COVID-19 virus and 86.3 percent against the B.1.17 variant, first identified in the United Kingdom. The company also announced results from a phase 2b trial in South Africa, which showed 48.6 percent efficacy overall but maintained 100 percent efficacy against severe disease. Phase 3 trials in the United States and Mexico are ongoing. Novavax plans to apply for regulatory approvals around the world, including for use by the global vaccine initiative COVAX, to which Novavax pledged to provide 1.1 billion doses.
South Africa trial shows promise for drug-resistant TB regimen Updated
AFP
Share this:
Almost all patients who received a new treatment for highly drug-resistant tuberculosis are still clear of the disease two years after a medical trial in South Africa, findings from a long-term study showed Thursday.
iStock
By comparison, five years ago if you were diagnosed with a drug resistant TB, at five years after diagnosis, eighty percent of people had passed on, lead researcher Dr. Pauline Howell told AFP on Thursday.
The findings, which have yet to be published, were presented this week at the annual Conference on Retroviruses and Opportunistic Infections (CROI), held online this year due to the Covid-19 pandemic.
SA trial shows promise for drug-resistant TB treatment – The Citizen citizen.co.za - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from citizen.co.za Daily Mail and Mail on Sunday newspapers.